AIFM2 and hepatocellular carcinoma: ACSL3, AIFM2, HSD17B7, LPCAT1, LSS, PLIN3 and RAB10 were up-regulated with the progression of cancer stage of HCC patients, while CIDEB, G0S2, HSD17B13, PLIN1 and PLIN2 were down-regulated (Fig. 3B).